CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
6E11 vg/eye of ADVM-022 +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04418427
NCT04418427Phase 2Completed
CompareCT.gov

A Phase 2, Multi-Center, Randomized, Double-Masked, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema [INFINITY]

Adverum Biotechnologies, Inc.·interventional·Posted Jun 5, 2020·Updated Jul 10, 2025

In Brief

A Phase 2 clinical trial evaluating 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, and 1 other intervention for Diabetic Macular Edema and Diabetic Retinopathy. Completed, enrolled 36 participants across 14 sites in 2 countries.

Detailed Summary

A Phase 2, Multi-Center, Randomized, Double-Masked\*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema \[INFINITY\]

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Macular Edema, Diabetic Retinopathy
CountriesPuerto Rico, United States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJun 5, 2020
Enrollment StartMay 28, 2020
Primary CompletionNov 22, 2022
Study CompletionJun 14, 2023
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 6.1 years ago

Interventions

6E11 vg/eye of ADVM-022biological

ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-incompetent adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept

2E11 vg/eye of ADVM-022biological

ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-incompetent adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept

Afliberceptbiological

Commercially available Active Comparator